日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CRISPR-Cas9 Screening Identifies Resistance Mechanisms to KRAS Inhibition in Pancreatic Cancer

CRISPR-Cas9筛选揭示胰腺癌中KRAS抑制的耐药机制

Long, Szu-Aun; Todd, Haley; Goodhart, Grace; Chang, Wen-Hsuan; Amparo, Amber M; Bridgens, Rachel; Dilly, Julien; Park, Se Jun; Beal, Robert M; Shehadeh, Sara M; Satyadi, Megan A; Trivedi, Vidushi K; Ackermann, Sarah E; Mukherjee, Raivath; Goodwin, Craig M; Edwards, A Cole; Stalnecker, Clint A; Greis, Kenneth D; Aguirre, Andrew J; Hobbs, G Aaron; Bryant, Kirsten L; Ahmad, Syed A; Cox, Adrienne D; Der, Channing J; Waters, Andrew M

Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer

MTA 协同 PRMT5 抑制剂 BMS-986504 与 KRAS 抑制剂联合使用是治疗 MTAP 缺失 KRAS 突变型胰腺癌的有效策略

Drizyte-Miller, Kristina; Engstrom, Lars D; Klomp, Jeffrey A; Stalnecker, Clint A; Stamey, Addison G; Taylor, Khalilah E; Roach, Mallory K; Robb, Ryan; Waters, Laura M; Calinisan, Andrew; Degan, Seamus; Chang, Wen-Hsuan; Helu, Xousaen M; Nguyen, David; Baldelli, Elisa; Pierobon, Mariaelena; Petricoin, Emanuel F; Briere, David M; Hallin, Jill; Christensen, James G; Bryant, Kirsten L; Cox, Adrienne D; Olson, Peter; Der, Channing J

Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve Is a Therapeutic Strategy for Pancreatic Cancer.

同时抑制 RAS-MAPK 通路和 PIKfyve 是胰腺癌的一种治疗策略

DeLiberty Jonathan M, Roach Mallory K, Stalnecker Clint A, Robb Ryan, Schechter Elyse G, Pieper Noah L, Taylor Khalilah E, Pita Lily M, Yang Runying, Bang Scott, Drizyte-Miller Kristina, Ackermann Sarah E, Nicewarner Peña Sheila R, Baldelli Elisa, Min Sophia M, Drewry David H, Petricoin Emanuel F 3rd, Morris John P 4th, Der Channing J, Cox Adrienne D, Bryant Kirsten L

Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

RAS-GTP 抑制对胰腺癌的肿瘤选择性活性

Urszula N Wasko #, Jingjing Jiang #, Tanner C Dalton, Alvaro Curiel-Garcia, A Cole Edwards, Yingyun Wang, Bianca Lee, Margo Orlen, Sha Tian, Clint A Stalnecker, Kristina Drizyte-Miller, Marie Menard, Julien Dilly, Stephen A Sastra, Carmine F Palermo, Marie C Hasselluhn, Amanda R Decker-Farrell, Step

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers

定义 KRAS 突变癌症中的 KRAS 和 ERK 依赖性转录组

Jeffrey A Klomp, Jennifer E Klomp, Clint A Stalnecker, Kirsten L Bryant, A Cole Edwards, Kristina Drizyte-Miller, Priya S Hibshman, J Nathaniel Diehl, Ye S Lee, Alexis J Morales, Khalilah E Taylor, Sen Peng, Nhan L Tran, Laura E Herring, Alex W Prevatte, Natalie K Barker, Laura D Hover, Jill Hallin,

Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers

定义KRAS突变癌症中KRAS和ERK依赖性转录组

Jeffrey A Klomp,Jennifer E Klomp,Clint A Stalnecker,Kirsten L Bryant,A Cole Edwards,Kristina Drizyte-Miller,Priya S Hibshman,J Nathaniel Diehl,Ye S Lee,Alexis J Morales,Khalilah E Taylor,Sen Peng,Nhan L Tran,Laura E Herring,Alex W Prevatte,Natalie K Barker,Laura D Hover,Jill Hallin,Alexey Sorokin,Preeti Marie Kanikarla,Saikat Chowdhury,Oluwadara Coker,Hey Min Lee,Craig M Goodwin,Prson Gautam,Peter Olson,James G Christensen,John P Shen,Scott Kopetz,Lee M Graves,Kian-Huat Lim,Andrea Wang-Gillam,Krister Wennerberg,Adrienne D Cox ,Channing J Der

Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer

与 CDK4/6 抑制剂联合治疗 KRAS 突变型胰腺癌

Craig M Goodwin, Andrew M Waters, Jennifer E Klomp, Sehrish Javaid, Kirsten L Bryant, Clint A Stalnecker, Kristina Drizyte-Miller, Bjoern Papke, Runying Yang, Amber M Amparo, Irem Ozkan-Dagliyan, Elisa Baldelli, Valerie Calvert, Mariaelena Pierobon, Jessica A Sorrentino, Andrew P Beelen, Natalie Bub

TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

TEAD 抑制剂可克服 YAP1/TAZ 驱动的对 KRASG12C 抑制剂的原发性和获得性耐药性

A Cole Edwards, Clint A Stalnecker, Alexis Jean Morales, Khalilah E Taylor, Jennifer E Klomp, Jeffrey A Klomp, Andrew M Waters, Niranjan Sudhakar, Jill Hallin, Tracy T Tang, Peter Olson, Leonard Post, James G Christensen, Adrienne D Cox, Channing J Der

VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in KRAS-mutant pancreatic cancer

VCP/p97 是一种多效性的 DNA 损伤反应和蛋白质稳态调节蛋白,是 KRAS 突变型胰腺癌的潜在治疗靶点

Ye S Lee, Jennifer E Klomp, Clint A Stalnecker, Craig M Goodwin, Yanzhe Gao, Gaith N Droby, Cyrus Vaziri, Kirsten L Bryant, Channing J Der, Adrienne D Cox

Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors

同时抑制 IGF1R 和 ERK 可增加胰腺癌对自噬抑制剂的敏感性

Clint A Stalnecker, Kajal R Grover, A Cole Edwards, Michael F Coleman, Runying Yang, Jonathan M DeLiberty, Björn Papke, Craig M Goodwin, Mariaelena Pierobon, Emanuel F Petricoin, Prson Gautam, Krister Wennerberg, Adrienne D Cox, Channing J Der, Stephen D Hursting, Kirsten L Bryant